Because clinical HCC samples frequently exhibited various Rb expression, such composite inhibition of both Rb-associated and Rb-unassociated CDKs may help broaden the clinical usefulness of dinaciclib in HCC. Here, RB1 is linked to hepatocellular carcinoma.